News | January 09, 2025
Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
Increases speed to market for drug developers working on nucleic acid therapeutics
Increases speed to market for drug developers working on nucleic acid therapeutics
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Subscribe To Our Newsletter & Stay Updated
